USPTO serial 88125988
KINTOR
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 13, 2020
- Examiner
- LAPTER, ALAIN J
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with KINTOR?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,446*
Plus Government fees of $1,700
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
SUZHOU KINTOR PHARMACEUTICALS, INC.
SUZHOU CITY, JIANGSU PROVINCE, CN
Other trademarks owned by SUZHOU KINTOR PHARMACEUTICALS, INC.
Grand Cayman, KY
Grand Cayman, KY
Grand Cayman, KY
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alex Patel
Alex Patel Patel IP, P.C.20700 Ventura Blvd., Suite 235Woodland Hills, CA 91364United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for treatment of cancer; sachets for pharmaceutical purposes, medicines in the form of capsules, chemico-pharmaceutical preparations, drugs for medical purposes, chemical preparations for pharmaceutical purposes, biological preparations for medical purposes, chemical preparations for medical purposes, all of the foregoing for the treatment of cancer; anti-cancer pharmaceutical preparations; pharmaceutical preparations for the diagnosis and treatment of cancer; pharmaceutical products for the prevention, diagnosis, treatment and adjunctive therapy of cancer, cardiovascular disease, nervous system diseases, infectious diseases, respiratory diseases, endocrine and metabolic diseases, mental disorder, skin disease, diseases of the blood system, digestive system diseases, immune system diseases, diseases of genitourinary system, ocular diseases, otolaryngology and dentistry diseases, musculoskeletal and connective tissue diseases, nutritional diseases, diseases caused by external factors, namely, poisoning and injury; compounds for treating cancer; pharmaceuticals, medical and veterinary preparations for the prevention, diagnosis, treatment and adjunctive therapy of cancer, cardiovascular disease, nervous system diseases, infectious diseases, respiratory diseases, endocrine and metabolic diseases, mental disorder, skin disease, diseases of the blood system, digestive system diseases, immune system diseases, diseases of genitourinary system, ocular diseases, otolaryngology and dentistry diseases, musculoskeletal and connective tissue diseases, nutritional diseases, diseases caused by external factors, namely, poisoning and injury; sanitary preparations for medical purposes; dietetic food and substances, namely, dietetic foods, sugar substitutes, nutritional beverages, and dietary supplements for weight loss adapted for medical and veterinary use; food for babies; dietary supplements for humans and animals; plasters and materials, namely, gauze for medical dressings; materials for dental fillings and for sealing purposes; dental wax; disinfectants; preparations for destroying vermin; fungicides; herbicides | ACTIVE | — |
| 035 | Retail pharmacy services; advertising services; business management; business administration services; providing office functions; information, advisory and consultancy services relating to all the aforesaid services | ACTIVE | — |
| 042 | Scientific and medical research services; pharmaceutical research services; research relating to pharmaceuticals; research and development of pharmaceutical products; biotechnology research; biochemistry and chemical research services; scientific research relating to biology and chemistry; scientific research in the field of pharmacy; scientific research into the development of new products; testing services for assessing the efficacy and safety of pharmaceuticals; preparation of reports relating to scientific research; analytical medical and scientific laboratory services; medical and scientific laboratory research and analysis; development of products; development of pharmaceutical preparations for the diagnosis and treatment of cancer; advisory services relating to scientific research; scientific and technological services in the field of pharmaceuticals and research and design relating thereto, namely, consulting and advisory services, CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) services; industrial analysis and research services in the field of pharmaceuticals; design and development of computer hardware and software; information, advisory and consultancy services relating to all the aforesaid services | ACTIVE | — |
| 044 | Pharmaceutical compounding services; providing medical information and information relating to the diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical advice in the field of medicine, pharmacology, medical analysis and diagnostics; provision of medical services in the field of alternative medicine; providing medical information relating to medicine, pharmacology and medical diagnosis; medicine and treatment prescription services, namely, services relating to the diagnosis of illness and prescription of medicine; medicine and treatment prescription services, namely, home health care services, managed health care services; physical therapy services; medical diagnostic testing, monitoring and reporting services; medical services; veterinary services; hygienic and beauty salon and consultation services for human beings and animals; medicine and treatment prescription services, namely, insecticide spraying, vermin extermination for agriculture, horticulture and forestry; information, advisory and consultancy services relating to all the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SUZHOU KINTOR PHARMACEUTICALS, INC.
- Other trademarks owned by Kintor Pharmaceutical Limited
- Other trademarks owned by Kintor Pharmaceutical Limited
- Other trademarks owned by Kintor Pharmaceutical Limited
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named KINTOR
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 13, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| May 7, 2025 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Apr 23, 2025 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Apr 23, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 23, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 23, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 13, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 4, 2020 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Sep 4, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 10, 2020 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Jul 10, 2020 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Jul 9, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jul 9, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 9, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Feb 14, 2020 | CHPB | POST PUBLICATION AMENDMENT - ENTERED | — |
| Feb 12, 2020 | APET | ASSIGNED TO PETITION STAFF | — |
| Jan 21, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 3, 2020 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Nov 26, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 26, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 6, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 20, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 15, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 15, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 14, 2019 | ALIE | ASSIGNED TO LIE | — |
| Oct 9, 2019 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jul 13, 2019 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jul 13, 2019 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jul 13, 2019 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jul 9, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 8, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 8, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 7, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 7, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 7, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 2, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 28, 2018 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Sep 27, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 24, 2018 | NWAP | NEW APPLICATION ENTERED | — |